Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer; and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”. Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice):

1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:

John G. Delinassios
International Institute of Anticancer Research (IIAR)
Editorial Office of ANTICANCER RESEARCH,
IN VIVO, CANCER GENOMICS and PROTEOMICS.
1st km Kapandritiou-Kalamou Road
P.O. Box 22, GR-19014 Kapandriti, Attiki
GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2010 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Cardiopulmonary Toxicity of Different Chemoradiotherapy Combined Regimens for Hodgkin’s Disease. A. BUSIA, A. LAFFRANCHI, S. VIVIANI, V. BONFANTE, F. VILLANI (Milan, Italy) ......................... 4381

Errata ................................................................................................................................. 4389

* Review (page 3889)
Contents continued

Prognostic Impact of Microsatellite Instability in Colorectal Cancer Patients Treated with Adjuvant FOLFOX. G. DES GUETZ, C. LECAILLE, P. MARIANI, M. BENNAMOUN, B. UZZAN, P. NICOLAS, A. BOISSEAU, X. SASTRE, J. CUCHEROUSSET, C. LAGORCE, P.O. SCHISCHMANOFF, J.F. MORERE (Bobigny; Bordeaux; Paris; Montfermeil, France) ................................................................. 4297

Life Stress due to Losses and Deficit in Childhood and Adolescence as Breast Cancer Risk Factor: A Prospective Case–Control Study in Kuopio, Finland. M. ESKELINEN, P. OLLONEN (Kuopio, Finland) .......................... 4303

TS, DHFR and GARFT Expression in Non-squamous Cell Carcinoma of NSCLC and Malignant Pleural Mesothelioma Patients Treated with Pemetrexed. H. URAMOTO, T. ONITSUKA, H. SHIMOKAWA, T. HANAGIRI (Kitakyushu, Japan) .............................................................. 4309

Metronomic Oral Cyclophosphamide Prednisolone Chemotherapy Is an Effective Treatment for Metastatic Hormone-refractory Prostate Cancer after Docetaxel Failure. S. LADOIRE, J.C. EYMARD, S. ZANETTA, G. MIGNOT, E. MARTIN, I. KERMARREC, E. MOUREY, F. MICHEL, L. CORMIER, F. GHIRINGHELLI (Dijon; Reims, France) ................................................................................................................ 4317

Irinotecan/Fluorouracil/Leucovorin or the Same Regimen Followed by Oxaliplatin/Fluorouracil/ Leucovorin in Metastatic Colorectal Cancer. H.P. KALOFONOS, P. PAPAKOSTAS, T. MAKATSORIS, D. PAPAMICHAEL, G. VOURLI, I. XANTHAKIS, G. ARAVANTINOS, C. PAPADIMITRIOU, G. PENTHEROUĐAKIS, I. VARTHALITIS, G. SAMELIS, K.N. SYRIGOS, N. XIROS, M. STAVROPOoulos, P. KOSMIDIS, C. CHRISTODOULOu, H. LINARDOU, M. SKONΔRA, D. PECTASIDES, T. ECONOMOPOoulos, G. FOUNTZILAS (Patras; Athens; Thessaloniki; Ioannina; Chania; Piraeus, Greece; Nicosia, Cyprus) ........................................................ 4325


Cytokeratin 19 Fragment/Carcinoembryonic Antigen Ratio in Pleural Effusion Is a Useful Marker for Detecting Malignant Pleural Mesothelioma. H. SUZUKI, T. HIRASHIMA, M. KOBAYASHI, S. SASADA, N. OKAMOTO, N. UEHARA, M. TAMIYA, Y. MATSUURA, N. MORISHITA, I. KAWASE (Osaka, Japan) ........................................ 4343

Disease-free Interval after Primary Treatment Predicts Prognosis of Recurrent Endometrial Carcinoma. Y. UEDA, Y. MATSUMURA, T. EGAWA-TAKATA, T. MIYAKE, T. MIYATAKE, K. YOSHINO, M. FUJITA, S. MATSUZAKI, T. YOKOYAMA, Y. MIYOSHI, M. YAMASAKI, T. ENOMOTO, T. KIMURA (Osaka, Japan) .................................................................................................................. 4347

High Prevalence of Human Anti-mouse Antibodies in the Serum of Colorectal Cancer Patients. M. GOTO, K. KURIBAYASHI, Y. UMEMORI, Y. OHE, K. ASANUMA, M. TANAKA, D. KOYASHI, N. WATANABE (Sapporo, Japan) .............................................. 4353

Carboplatin plus Weekly Paclitaxel Treatment in Non-small Cell Lung Cancer Patients with Interstitial Lung Disease. T. SHUKUYA, T. ISHIWATA, M. HARA, K. MURAKI, R. SHIBAYAMA, R. KOYAMA, K. TAKAHASHI (Tokyo, Japan) ......................................................................................................................... 4357

Immunochemical Staining of MT2-MMP Correlates Positively to Angiogenesis of Human Esophageal Cancer. L. CHEN, D. DI, G. LUO, L. ZHENG, Y. TAN, X. ZHANG, N. XU (Changzhou, Jiangsu, PR China; Lund, Sweden) ............................................................................................................................. 4363

Prognostic Value of IL-6 in Localized Prostatic Cancer. J. ALCOVER, X. FILELLE, P. LUQUÉ, R. MOLINA, L. IZQUIERDO, J.M. AUGÉ, A. ALCARAZ (Barcelona, Spain) ........................................................................................................ 4369

Contents continued on the preceding page

EGFR-Activating Mutations Are Not Present in Breast Tumors of Japanese Patients. H. URAMOTO, H. SHIMOKAWA, Y. NAGATA, K. ONO, T. HANAGIRI (Kitakyushu, Japan) ........................................... 4219

L-type Amino-Acid Transporter 1 Expression Predicts the Response to Preoperative Hyperthermo-Chemoradiotherapy for Advanced Rectal Cancer. T. EBARA, K. KAIRA, J.-I. SAITO, M. SHIOYA, T. ASAO, T. TAKAHASHI, H. SAKURAI, Y. KANAI, H. KUWANO, T. NAKANO (Maebashi, Gunma; Ibaraki; Osaka, Japan) ....................................................... 4223


Use of Paclitaxel for Advanced Ovarian Cancer in Clinical Practice: Analysis of 541 Patients. Results from a German Multi-centre Observational Study. J. SEHOULI, G. OSKAY-ÖZCELIK (Berlin, Germany) ..........

Impact of Tumor Biology, Particularly Triple-negative Status, on Response to Pre-operative Sequential, Dose-dense Epirubicin, Cyclophosphamide Followed by Docetaxel in Breast Cancer. M. WARM, R. KATES, E.M. GROSSE-ONNEBRINK, M. STOFF-KHALILI, M. HOOPMANN, A. THOMAS, N. HARBECK (Cologne; Otterfing; Berlin, Germany) .......................................................... 4251


Atlanto-occipital Ligament Calcification: A Novel Sign in Nevoid Basal Cell Carcinoma Syndrome. R. LEONARDI, A. SANTARELLI, E. BARBATO, D. CIVARELLA, S. BOLOURI, F. HÄRLE, G. PALAZZO, L. LO MUZIO (Catania; Foggia; Rome; Rioniero in Vulture, Italy; Kiel, Germany) .............. 4265

Dual Role of RASSF1 as a Tumor Suppressor and an Oncogene in Neuroendocrine Tumors of the Lung. G. PELOSI, C. FUMAGALLI, M. TRUBIA, A. SONZOGNI, N. REKHTMAN, P. MAISONNEUVE, D. GALETTA, L. SPAGGIARI, G. VERONESI, A. SCARPA, G. MALPELI, G. VIALLE (Milan; Verona, Italy; New York, NY, USA) .............................................................. 4269

Late Metastasis of Gastrointestinal Stromal Tumour to the Oral Cavity. R.E. FRIEDRICH, J. ZUSTIN (Hamburg, Germany) ............................................................................................................ 4283

Clinical and Molecular Determinants of Survival in Pancreatic Cancer Patients Treated with Second-line Chemotherapy: Results of an Italian/Swiss Multicenter Survey. A. MANCUSO, S. SACCHETTA, P.C. SALETTI, C. TRONCONI, L. MILESI, M. GARASSINO, O. MARTELLI, A. LEONE, A. ZIVI, L. CERBONE, F. RECINE, R. SOLLAMI, R. LABIANCA, F. CAVALDI, C.N. STERNBERG (Rome; Milan; Bergamo, Italy; Bellinzona, Switzerland) ................................................................................................. 4289

Contents continued on the preceding page


The Joint Effect of hOGG1 Single Nucleotide Polymorphism and Smoking Habit on Lung Cancer in Taiwan. C.-J. LIU, T.-C. HSIA, R.-Y. TSAI, S.-S. SUN, C.-H. WANG, C.-C. LIN, C.-W. TSAI, C.-Y. HUANG, C.-M. HSU, D.-T. BAU (Taichung, Taiwan, ROC) ..........................................................................

CRIM1 is Expressed at Higher Levels in Drug-resistant than in Drug-sensitive Myeloid Leukemia HL60 Cells. M. PRENKERT, B. UGGLA, U. TIDEFELT, H. STRID (Örebro, Sweden)..........................................................................


Differential Suppression of Proliferation in MCF-7 and MDA-MB-231 Breast Cancer Cells Exposed to α-, γ- and δ-Tocotrienols Is Accompanied by Altered Expression of Oxidative Stress Modulatory Enzymes. T.-C. HSIEH, S. ELANGOVAN, J.M. WU (Valhalla, NY, USA)..........................................................................


The Novel Quinolone CHM-1 Induces DNA Damage and Inhibits DNA Repair Gene Expressions in a Human Osteogenic Sarcoma Cell Line. H.-Y. CHEN, H.-F. LU, J.-S. YANG, S.-C. KUO, C. LO, M.-D. YANG, T.-H. CHIU, F.-S. CHUEH, H.-C. HO, Y.-C. KO, J.-G. CHUNG (Taipei; Taichung; Chia yi, Taiwan, ROC)....

Inhibition of Myc Effectively Targets KRAS Mutation-positive Lung Cancer Expressing High Levels of Myc. T. FUKAZAWA, Y. MAEDA, J. MATSUOKA, T. YAMATSUJI, K. SHIGEMITSU, I. MORITA, F. FALIO, M.L. DURBIN, L. SOUCEK, Y. NAOMOTO (Okayama, Japan; Cincinnati, OH; Riverside; Irvine; San Francisco, CA, USA)..........................................................................

Antitumour and Cytogenetic Effects of Modified Steroidal Derivatives of Propenoic Acid: In Vivo/In Vitro Studies. A. PAPAGEORGI OU, C. MOURELATOS, G. GEROMICHALOS, E. GEROMICHALOU, P. DALEZIS, T. LIALIARIS (Thessaloniki; Alexandroupolis; Ioannina, Greece) ..........................................................................

The Joint Effect of hOGG1 Single Nucleotide Polymorphism and Betel Quid Chewing on Oral Cancer in Taiwan. Y.-A. TSAOU, C.-H. HUA, H.-C. TSENG, C.-F. HSU, C.-W. TSAI, S.-S. SUN, R.-Y. TSAI, M.-H. TSAI, D.-T. BAU (Taichung; Chang-Hua, Taiwan, ROC).............................................................................
Studies on Combinations of Platinum with Paclitaxel and Colchicine in Ovarian Cancer Cell Lines. N.M. YUNOS, P. BEALE, J.Q. YU, D. STRAIN, F. HUQ (Sydney, NSW, Australia; Kepong Selangor, Malaysia) ................................................................. 4025


Reversal of Multidrug Resistance in Murine Lymphoma Cells by Amphiphilic Dihydropyridine Antioxidant Derivative. M. CINDRIC, A. CIPAK, J. SERLY, A. PLOTNIECE, M. JAGANJAC, T. LOVAKOVIC, A. DEDIC, I. SOLDGO, N. ZARKOVIC, J. MOLNÁR (Zagreb; Osijek, Croatia; Szeged, Hungary; Riga, Latvia; Vienna, Austria) ................................................................................................................................. 4063

γ-Secretase Inhibitors Induce Erythroid Differentiation in Erythroid Leukemia Cell Lines. Y. OKUHASHI, M. ITOH, A. ARAI, N. NARA, S. TOHDA (Tokyo, Japan) ................................................................................................................................. 4071

Nanodiamond and Nanoplatinum Liquid, DPV576, Activates Human Monocyte-derived Dendritic Cells In Vitro. M. GHONEUM, A. GHONEUM, J. GIMZEWSKI (Los Angeles, CA, USA) ................................................................................................................................. 4075


Bacillus Calmette-Guerin and BCG Cell Wall Skeleton Suppressed Viability of Bladder Cancer Cells In Vitro. T. KATO, V. BILIM, K. YUUKI, S. NAITO, T. YAMANOB, A. NAGAO, I. YANO, H. AKAZA, Y. TOMITA (Yamagata; Tokyo; Ibaraki-ken, Japan) ................................................................................................................................. 4089

Soluble MICB Serum Levels Correlate with Disease Stage and Survival Rate in Patients with Oral Squamous Cell Carcinoma. S. TAMAKI, M. KAWAKAMI, A. ISHITANI, W. KAWASHIMA, S. KASUDA, Y. YAMANAKA, H. SHIMOMURA, Y. IMAI, Y. NAKAGAWA, K. HATAKE, T. KIRITA (Kashiwara, Nara, Japan) ................................................................................................................................. 4097


Significance of Keratinocyte Growth Factor Receptor in the Proliferation of Biliary Tract Cancer. R. AMANO, N. YAMADA, Y. DOI, M. YASHIRO, M. OHIRA, A. MIWA, K. HIRAKAWA (Osaka; Tokyo, Japan) ................................................................................................................................. 4115

Further Studies on Barretts Mucosa in Baboons: Metaplastic Glandular Cells Produce Sialomucin. C.A. RUBIO, M. OWSTON, A. ORREGO, E.J. DICK Jr. (San Antonio, TX, USA) ................................................................................................................................. 4123

Methylation-mediated Silencing of TMS1 in Pancreatic Cancer and its Potential Contribution to Chemosensitivity. K. RAMACHANDRAN, H. MILLER, E. GORDIAN, C. ROCHA-LIMA, R. SINGAL (Miami, FL, USA) ................................................................. 3919

Second-generation Substituted Quinolines as Anticancer Drugs for Breast Cancer. B. HEINIGER, G. GAKHAR, K. PRASAIN, D.H. HUA, T.A. NGUYEN (Manhattan, KS, USA) ................................................................. 3927

Orthotopic Fluorescent Peritoneal Carcinomatosis Model of Esophageal Cancer. S.J. GROS, T. DOHRMANN, T. RAWNAQ, N. KURSCHAT, M. BOUDET, J. WESSELS, R.M. HOFFMANN, J.R. IZBICKI, J.T. KAIFI (Hamburg; Goettingen, Germany; San Diego, CA, USA) ................................................................. 3933

A Positive Relationship Between Filamin and VEGF in Patients with Lung Cancer. H. URAMOTO, L.M. AKYÜRERK, T. HANAGIRI (Kitakyushu, Japan; Gothenburg, Sweden) ................................................................. 3939

Effects of ILTG on DAPK1 Promoter Methylation in Colon and Leukemia Cancer Cell Lines. B.A ZORKO, L.B. PÉREZ, E.J. CARCACHE DE BLANCO (Columbus, OH, USA) ................................................................. 3945

Inhibition of GST-pi Nuclear Transfer Increases Mantle Cell Lymphoma Sensitivity to Cisplatin, Cytarabine, Gencitabine, Bortezomib and Doxorubicin. D. ROLLAND, M. RAHARJAONA, A. BARBARAT, R. HOULGATTE, C. THIEBLEMONT (Grenoble; Nantes; Lyon; Paris, France) ................................................................. 3951

IL-1 Receptor Antagonist Anakinra Enhances Tumour Growth Inhibition in Mice Receiving Peptide Vaccination and β-(1-3),(1-6)-D-Glucan. U. HARNACK, H. JOHNEN, G. PechER (Berlin, Germany) ................................................................. 3959

Salen-Manganese Complexes: Sophisticated Tools for the Analysis of Intercellular ROS Signaling Pathways. S.J. OPHOVEN, G. BAUER (Freiburg, Germany) ................................................................. 3967

Endocrine Gland Derived-VEGF Is Down-regulated in Human Pituitary Adenoma. M. RAICA, M. COCULESCU, A.M. CIMPEAN, D. RIBATTI (Timisoara; Bucharest, Romania; Bari, Italy) ................................................................. 3981

Evaluation of In Vitro Biological Activity of O-Alkylated Hydroxamic Derivatives of Some Nonsteroidal Anti-inflammatory Drugs. S. KRALJEVIĆ PAVELIĆ, M. SEDIĆ, M. POZNIĆ, Z. RAJIĆ, B. ZORC, K. PAVELIĆ, J. BALZARINI, M. MINTAS (Rijeka; Zagreb, Croatia; Leuven, Belgium) ................................................................. 3987

PKCa/β I Inhibitor Go6976 Induces Dephosphorylation of Constitutively Hyperphosphorylated Rb and G1 Arrest in T24Cells. V. AALTONEN, J. PELTONEN (Turku, Finland) ................................................................. 3995

Staining with Highly Sensitive Coomassie Brilliant Blue SeePico™ Stain after Flamingo™ Fluorescent Gel Stain Is Useful for Cancer Proteomic Analysis by Means of Two-dimensional Gel Electrophoresis. Y. KURAMITSU, E. HAYASHI, F. OKADA, X. ZHANG, T. TANAKA, Y. UEYAMA, K. NAKAMURA (Ube; Yamagata, Japan) ................................................................. 4001

Curcumin-altered p53-Response Genes Regulate Radiosensitivity in p53-Mutant Ewing’s Sarcoma Cells. J. VEERARAGHAVAN, M. NATARAJAN, T.S HERMAN, N. ARAVINDAN (Oklahoma City, OK; San Antonio, TX, USA) ................................................................. 4007

Antiproliferative Effects of Rapamycin and Celecoxib in Angiosarcoma Cell Lines. A. BUNDSCHERER, T. VOGT, G. KOHL, M. LANDTHALER, C. HAFNER (Regensburg, Germany) ................................................................. 4017

Contents continued on the preceding page